Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBIT (2016 - 2025)

Historic EBIT for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to $1.2 million.

  • Usana Health Sciences' EBIT fell 9215.43% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.8 million, marking a year-over-year decrease of 4920.26%. This contributed to the annual value of $66.3 million for FY2024, which is 2873.83% down from last year.
  • Usana Health Sciences' EBIT amounted to $1.2 million in Q3 2025, which was down 9215.43% from $16.7 million recorded in Q2 2025.
  • Over the past 5 years, Usana Health Sciences' EBIT peaked at $53.7 million during Q3 2021, and registered a low of $1.2 million during Q3 2025.
  • In the last 5 years, Usana Health Sciences' EBIT had a median value of $24.2 million in 2023 and averaged $25.6 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 3570.45% in 2021, then crashed by 9215.43% in 2025.
  • Usana Health Sciences' EBIT (Quarter) stood at $40.8 million in 2021, then tumbled by 44.69% to $22.6 million in 2022, then rose by 7.4% to $24.2 million in 2023, then plummeted by 66.1% to $8.2 million in 2024, then plummeted by 85.09% to $1.2 million in 2025.
  • Its EBIT stands at $1.2 million for Q3 2025, versus $16.7 million for Q2 2025 and $15.7 million for Q1 2025.